39 results about "Corneal endothelial cell" patented technology

The invention discloses application of ganoderma lucidum exosomes in preparation of corneal injury repair preparations, and belongs to the technical field of biological medicines. The ganoderma lucidum exosome realizes corneal injury repair by promoting corneal endothelial cell proliferation and migration ability, promotes corneal endothelial proliferation and cell migration and accelerates corneal endothelial injury repair through an EGFR / ERK signal channel, can be used for treatment of corneal epithelium defect related ocular surface diseases, corneal lesion and other diseases, and has a wide application prospect. And a new thought is provided for treatment of corneal endothelial diseases.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The utility model relates to the field of medical instruments, in particular to an eye microneedle cornea patch structure and a mold for preparing an eye microneedle cornea patch, which can prevent a microneedle on a microneedle substrate from damaging a cornea sclera marginal structure and cornea endothelial cells and further reduce damage to eyes of a patient in microneedle treatment. Comprising a microneedle substrate matched with an eyeball contour curved surface, a microneedle is arranged on the inner side wall face of the microneedle substrate and extends in the direction perpendicular to the inner side wall face of the microneedle substrate, a substrate through hole is formed in the geometric center of the microneedle substrate, the diameter of the microneedle substrate is smaller than that of a cornea, the diameter of the substrate through hole is not smaller than 4 mm, and the diameter of the substrate through hole is larger than or equal to 5 mm. And the microneedles are uniformly arranged on the microneedle substrate around the substrate through hole.

The present invention provides a method for determining the quality of cultured corneal endothelial cells (CECs) comprising measuring in or on a cultured CEC a level of expression of the genes Thrombospondin-2 (THBS2) and / or Vitelline Membrane Outer Layer 1 Homolog (VMO1), and determining that the quality of said cultured CEC is non-therapy-grade if said measured level of expression corresponds to a THBS2+ and / or VMO1+ expression profile.

The present invention aims to provide a cell inoculum and a cell transplantation substrate which can be subcultured without causing cell transformation and can effectively implant cells. An inoculum and a transplantation substrate containing a phenolphthalein derivative for facilitating implantation of cultured corneal endothelial cells or corneal endothelial replacement cells. The inoculum and the transplantation substrate can facilitate adhesion of cells during subculture and implantation of cells during transplantation.

The present disclosure provides a method for cryopreserving corneal endothelial cells and / or corneal endothelial-like cells, and a freezing prepartaion for corneal endothelial cells and / or corneal endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and / or corneal endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and / or corneal endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C / min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and / or the corneal endothelial-like cells in a frozen state.

Congenital hereditary endothelial dystrophy (CHED) is an autosomal recessive condition affecting the corneal endothelial cells, which function to maintain corneal clarity. Currently there is no highly efficacious treatment available for CHED caused by SLC4A11 gene mutations. The invention disclosed herein includes mammalian vectors for use in the treatment of Congenital hereditary endothelial dystrophy and methods for using such vectors.

The present application relates to the technical field of medical data processing, in particular to a cataract ultrasonic emulsification postoperative corneal rehabilitation evaluation system based on deep learning. The system comprises an image acquisition module for acquiring postoperative corneal endothelial cell images of a person; a first abnormality analysis module for extracting abnormal corneal regions in the corneal endothelial cell images; a second abnormality analysis module for screening out suspected mechanical damage regions from the abnormal corneal regions; a region segmentation module for segmenting the suspected mechanical damage regions into suspected damage sub-regions; a region division module for determining the division parameters of the suspected damage sub-regions belonging to mechanical damage; based on the pixel number, area and corresponding division parameters in the suspected damage sub-regions, determining the rehabilitation degree, and dividing the suspected damage sub-regions into mechanical damage regions and hyperglycemia damage regions. The present application improves the accuracy of segmentation of mechanical damage regions and hyperglycemia damage regions.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

1. Name of the product in this design: Corneal endothelial cell counter. 2. Purpose of this design: This design is used as an ophthalmic device for evaluating the density, morphology and function of corneal endothelial cells. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Human embryonic stem cell (hESC)- and induced pluripotent stem cell (iPSC)-derived clinical-grade corneal endothelial cells (CECs) generation and cryopreservation through the neural crest cell (NCC) lineage using peripheral blood as a donor source and hESCs maximizes the availability of these vital cells for treating the corneal endothelial disease as an alternative to donor corneas for corneal endothelium (CE) transplantations and other applications.

The present invention refers to an in vitro or ex vivo method for reversing and / or reducing and / or inhibiting the endothelial to mesenchymal transition (EnMT) process in corneal endothelial cells, preferably in primary and / or human corneal endothelial cells, more preferably primary human corneal endothelial cells (HCEnCs), said method comprising the step of incubating said cells with at least one inhibitor of glycogen synthase kinase 3 (GSK-3).

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

The present invention complete a technique of treating a corneal disorder or disease by infusion into an anterior chamber of human eyes. Specifically, the present invention based on the findings discovered that cultured human corneal endothelial cells are comprised of a plurality of subpopulations, most of them are not suitable for infusion into patients. The above-described subject was overcome by providing, as a medicament, functionally high grade quality of cells having the function of mature differentiated human corneal endothelial cells which is a specific subpopulation and characterized by their biochemical and functional phenotypes. The present invention provides such a functional mature differentiated corneal endothelial cells, medicament comprising, the same, and manufacturing method, quality control and techniques related thereto.

The present invention provides a method for establishing a corneal endothelial cell finite element model, which includes importing a standard corneal model into finite element preprocessing software and generating a 2D grid to obtain a base grid model, importing a detailed geometric model of the corneal endothelial cell, determining a complete corneal endothelial cell model based on the base grid model and the detailed geometric model, and performing calculations based on the complete corneal endothelial cell model. The present invention can improve the efficiency and effectiveness of establishing a corneal endothelial cell finite element model.

The present invention belongs to the technical field of drug preparation and relates to a nicotinamide-containing intraocular surgical irrigation solution and its preparation and application. The present invention provides the use of nicotinamide in an intraocular surgical irrigation solution. The present invention uses nicotinamide to improve the intraocular surgical irrigation solution, which can inhibit corneal endothelial cell damage caused by cataract phacoemulsification surgery, reduce corneal edema caused by cataract phacoemulsification surgery, avoid a significant decrease in the number of corneal endothelial cells caused by surgery, promote the recovery of corneal transparency after surgery, promote the recovery of normal corneal thickness, maintain the normal density, cell morphology, and regular expression of functional proteins of corneal endothelial cells, and reduce complications caused by cataract phacoemulsification surgery. The present invention can provide an effective strategy for the rapid recovery of normal visual function in cataract patients after surgery.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

The invention provides application of a deep eutectic solvent in preparation of a medicine for promoting adeno-associated virus anterior chamber transfection, and belongs to the technical field of medicine preparation. The invention relates to an application of a deep eutectic solvent in preparation of drugs for promoting adeno-associated virus or genetically modified adeno-associated virus transfection. The deep eutectic solvent is prepared from choline chloride and fructose in a molar ratio of 2: 1. The deep eutectic solvent (DES) has moderate viscosity and approximately clear and transparent appearance, can stay in an anterior chamber for a certain time without blocking chamber corners, has the advantages of low toxicity, biodegradability, simplicity and convenience in synthesis and the like, and can be used as a delivery carrier of an adeno-associated virus (AAV). The DES is injected into the animal model in the anterior chamber, the DES cannot cause changes of corneal transparency, corneal thickness, corneal barrier function, pump function and corneal endothelial cell morphology, the safety is good, the anterior chamber AAV transfection efficiency can be improved, and outflow of AAV along with aqueous humor circulation and immunogenicity are reduced.

Cryopreservation of endothelial cell monolayers is one of the major challenges in the cryopreservation of complex tissues. Human umbilical vein endothelial cells (HUVECs) in suspension are available commercially and recently their post-thaw cell membrane integrity was significantly improved by cryopreservation in 5% dimethyl sulfoxide (DMSO) and 6% hydroxyethyl starch (HES). However, cryopreservation of cells in monolayers has been elusive. The exact mechanisms of damage during cell monolayer cryopreservation are still under investigation. Here, we show that a combination of different factors contribute to significant progress in cryopreservation of cell monolayers. The addition of 2% chondroitin sulfate to 5% DMSO and 6% HES and cooling at 0.2 or 1° C. / min led to high membrane integrity (97.3±3.2%) immediately after thaw when HUVECs were cultured on a substrate with a coefficient of thermal expansion similar to that of ice. The optimized cryopreservation protocol was applied to monolayers of primary porcine corneal endothelial cells, and resulted in high post-thaw viability (95.9±3.7% membrane integrity) with metabolic activity 12 hours post-thaw comparable to unfrozen control.

A method for preparing an exosome includes: cultivating corneal stromal keratocytes (CSKs) in a culture medium containing vitamin C, so as to obtain a cell culture of the CSKs containing the exosome; and subjecting the cell culture to an isolation treatment, so as to obtain the exosome. An exosome prepared by the aforesaid method, and methods for promoting proliferation of corneal endothelial cells and improving wound healing in a corneal endothelium using the exosome are also provided.

The invention discloses a method for promoting differentiation of cranial nerve crest cells into corneal endothelial cells. According to the method, a culture medium with definite chemical components is used for inducing differentiation of the nerve crest cells into the corneal endothelial cells. The method provided by the invention has the advantages of high induced differentiation efficiency, strong stability, clear culture system components, high safety and the like, and is suitable for large-scale induced differentiation culture of corneal endothelial cells; and the prepared corneal endothelial cell is highly consistent with the primary corneal endothelial cell in the aspects of contact inhibition, ion transport, metabolic function and the like, and has huge market value and wide application prospect.

Human corneal endothelial cells and / or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and / or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and / or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.

The present invention provides cell trait assay techniques which identify cultured human corneal endothelial cells that, in a clinical trial, have been confirmed to express early-stage clinical effects and provide clinical effects that are stable in the long term. Provided is a method for producing functional human corneal endothelial cells which can bring about human corneal function when injected into the anterior chamber of a human eye, said method including a step for growing and / or differentiating / maturing corneal endothelium precursor cells under culturing conditions that can minimize culturing stress such as growth stress. Also provided are functional human corneal endothelial cells which have been found to express a functional protein leading to corneal endothelium (cell) functional characteristics that improve corneal clouding and hydration swelling, and, as a result, sustainably maintain corneal endothelium tissue cell density in the long term and lead to eyesight improvement, or in which proteins that inhibit such corneal endothelium (cell) functional characteristics are have not been elicited or are reduced.

The invention provides an application of a pigment epithelium-derived factor in the aspect of treating or relieving corneal endothelial dystrophy and corneal endothelial dysfunction, in particular to an application of the pigment epithelium-derived factor in preparation of drugs for treating or relieving corneal endothelial dystrophy and corneal endothelial dysfunction. The PEDF is used for treating Fuchs corneal endothelial dystrophy for the first time, and it is proved that the PEDF can effectively relieve corneal endothelial cell injury, remarkably promote corneal transparency and thickness recovery, relieve corneal edema and promote corneal endothelial cell density, morphological repair and functional reconstruction. The method has good social value, PEDF medicine treatment has the advantages of being sufficient in source, easy and convenient to operate, low in treatment cost, small in risk and the like, and the requirements of corneal transplantation surgery in clinic can be reduced.

The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin, and combinations thereof.